Sep 30, 2024 · At Scholar Rock, we are on a mission to discover, develop, and deliver therapies to improve people’s lives. We are a biopharmaceutical company combining bold science with a deep commitment to make a meaningful difference for people living with serious diseases.

We seek partnerships that accelerate scientific innovation and advance our mission to discover, develop, and deliver life-changing therapies. Like what you see? Visit our Careers page to see if Scholar Rock is the right fit for your next step.

Scholar Rock offers unique opportunities to apply your expertise and insights within a focused, commercial-ready environment, so you can continue growing professionally in both knowledge and skills.

Feb 4, 2021 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a...

Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need.

Feb 25, 2025 · Scholar Rock's commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity.

Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases. Scholar Rock Holding showed a rising price performance with a jump to an 83 RS rating. View contacts for Scholar Rock to access new leads and connect with decision-makers.

May 24, 2021 · Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA.

Sep 19, 2023 · Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at …

To identify therapeutics, Scholar Rock is using their proprietary platform to develop antibody drugs that recognise the prodomain of precursor growth factors. Scholar Rock’s lead candidate, Apitegromab, is in Phase 3 clinical trials for patients with Spinal Muscular Atrophy.